文献速递糖尿病

美国 Medicare 受益人新发 2 型糖尿病归因的终身医疗支出:基于 1999-2019 年全国 Medicare 索赔数据的纵向研究

Lifetime Medical Spending Attributed to Incident Type 2 Diabetes in Medicare Beneficiaries: A Longitudinal Study Using 1999-2019 National Medicare Claims.
PubMed 文献 · Diabetes Care · 2024-01-01

研究利用 1999-2019 年 Medicare 按服务收费索赔数据库,识别 2001-2003 年新诊断 2 型糖尿病的受益人队列,并以倾向评分匹配无糖尿病队列,随访至死亡、退保或 2019 年底。新诊断 2 型糖尿病受益人尽管预期寿命更短,终身医疗支出仍比无糖尿病对照组高 36-40%,终身增量医疗支出为 16,115 至 122,146 美元,随诊断年龄增加而下降,在亚裔/太平洋岛民和非西班牙裔黑人中最高。

要点

  • 新诊断 2 型糖尿病 Medicare 受益人终身医疗支出比无糖尿病对照组高 36-40%。
  • 终身增量医疗支出为 16,115 至 122,146 美元,随诊断年龄增加而下降。
  • 亚裔/太平洋岛民和非西班牙裔黑人受益人的终身增量医疗支出最高。

核心结论

  • 新发 2 型糖尿病相关的巨额终身增量医疗支出凸显了在 Medicare 受益人中预防 2 型糖尿病的必要性。
  • 研究结果可用于估计 2 型糖尿病预防项目在总体和受益人亚组中的潜在经济获益。

研究设计与样本

  • 利用 1999-2019 年 100% Medicare 按服务收费索赔数据库,通过 ICD 编码识别 2001-2003 年新诊断 2 型糖尿病的受益人队列。
  • 采用倾向评分方法将新诊断 2 型糖尿病队列与无糖尿病队列匹配,随访两队列至死亡、退保或 2019 年底。
  • 终身医疗支出为从 2 型糖尿病诊断年龄至死亡的预期年度支出之和,即实际年度支出乘以年度生存率;终身增量医疗支出为两队列终身医疗支出之差;所有支出标准化为 2019 年美元。

主要发现

  • 新诊断 2 型糖尿病 Medicare 受益人尽管预期寿命更短,终身医疗支出比无糖尿病对照组高 36-40%。
  • 终身增量医疗支出为 16,115 至 122,146 美元,取决于诊断年龄、性别和种族/民族。
  • 终身增量医疗支出随诊断年龄增加而下降,在亚裔/太平洋岛民和非西班牙裔黑人受益人中最髙。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate lifetime incremental medical spending attributed to incident type 2 diabetes (T2D) among Medicare beneficiaries by age at diagnosis, sex, and race/ethnicity. RESEARCH DESIGN AND METHODS: We used the 1999-2019 100% Medicare fee-for-service claims database to identify a cohort of beneficiaries with newly diagnosed T2D in 2001-2003 using ICD codes. We matched this cohort with a nondiabetes cohort using a propensity score method and then followed the two cohorts until death, disenrollment, or the end of 2019. Lifetime medical spending for each cohort was the sum of expected annual spending, a product of actual annual spending multiplied by the annual survival rate, from the age at T2D diagnosis to death. Lifetime incremental medical spending was calculated as the difference in lifetime medical spending between the two cohorts. All spending was standardized to 2019 U.S. dollars. RESULTS: Medicare beneficiaries with newly diagnosed T2D, despite having a shorter life expectancy, had 36-40% higher lifetime medical spending compared with a comparable group without diabetes. Lifetime incremental medical spending ranged from $16,115 to $122,146, depending on age at diagnosis, sex, and race/ethnicity, declining with age at diagnosis, and being highest for Asian/Pacific Islander and non-Hispanic Black beneficiaries. CONCLUSIONS: The large lifetime incremental medical spending associated with incident T2D underscores the need for preventing T2D among Medicare beneficiaries. Our results could be used to estimate the potential financial benefit of T2D prevention programs both overall and among subgroups of beneficiaries.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Shao Y, Wang Y, Bigman E, et al. Lifetime Medical Spending Attributed to Incident Type 2 Diabetes in Medicare Beneficiaries: A Longitudinal Study Using 1999-2019 National Medicare Claims. Diabetes Care. 2024. PMID: 38913956. doi:10.2337/dc24-0466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。